Effect of immunomodulation with human interferon-β on early functional recovery from experimental spinal cord injury

Spine

Volumn 32, Issue 8, 2007, Pages 873-880

  Gok, Beril ^a,d   Okutan, Ozerk ^a   Beskonakli, Etem ^a   Palaoglu, Selcuk ^c   Erdamar, Husamettin ^b   Sargon, Mustafa F ^c  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b BEYTEPE MILITARY HOSPITAL   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

^d NONE   (Turkey)

Author keywords

Histopathology; Immunomodulation therapy; Interferon ; Methylprednisolone; Myeloperoxidase; Neuroprotection; Oxygen free radicals; Spinal cord injury

Indexed keywords

INTERFERON BETA SERINE; METHYLPREDNISOLONE SODIUM SUCCINATE; MUSTAFA NEVZAT; MYELOPEROXIDASE; THIOBARBITURIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DRUG EFFECT; DRUG EFFICACY; ELECTRON MICROSCOPY; FEMALE; IMMUNOMODULATION; IMMUNOTHERAPY; LIPID PEROXIDATION; NEUROLOGIC EXAMINATION; NEUROPROTECTION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; RAT; RATING SCALE; SINGLE DRUG DOSE; SPINAL CORD INJURY; TISSUE STRUCTURE;

ACUTE DISEASE; ANIMALS; BIOLOGICAL RESPONSE MODIFIERS; FEMALE; HUMANS; INTERFERON-BETA; LIPID PEROXIDATION; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA; NERVE FIBERS, MYELINATED; NEURONS; NEUROPROTECTIVE AGENTS; PEROXIDASE; RATS; RATS, WISTAR; RECOVERY OF FUNCTION; SPINAL CORD; SPINAL CORD INJURIES;

EID: 34247244186     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/01.brs.0000259841.40358.8f     Document Type: Article

References (48)

1. Tator CH, Fehlings MG. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg 1991;75:15-26.
2. Hauben E, Schwartz M. Therapeutic vaccination for spinal cord injury: helping the body to cure itself. Trends Pharmacol Sci 2003;24:7-12.
3. Popovich PG. Immunological regulation of neuronal degeneration and regeneration in the injured spinal cord. Prog Brain Res 2000;128:43-58.
4. Profyris C, Cheeema SS, Zang DW, et al. Degenerative end regenerative mechanisms governing spinal cord injury. Neurobiol Dis 2004;15:415-36.
5. Carlson SL, Parrish ME, Springer JE, et al. Acute inflammatory response in spinal cord following impact injury. Exp Neurol 1998;151:77-88.
6. Hamada Y, Ikata T, Katoh S, et al. Involvement of an intracellular adhesion molecule-dependent pathway in the pathogenesis of secondary changes after spinal cord injury in rats. J Neurochem 1996;32:192-4.
7. Schnell L, Fearn S, Klassen H, et al. Acute inflammatory responses to mechanical lesions in the CNS: differences between brain and spinal cord. Eur J Neurosci 1999;11:3648-58.
8. Kallmann BA, Hummel V, Lindenlaub T, et al. Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. Brain 2000;123:687-97.
9. Di Castro RC Jr, Burns CL, McAdoo DJ, et al. Metalloproteinase increases in the injured rat spinal cord. Neuroreport 2000;11:3551-4.
10. Goussev S, Hsu JY, Lin Y, et al. Differential temporal expression of matrix metalloproteinases after spinal cord injury: relation to revascularization and wound healing. J Neurosurg 2002;99:188-92.
11. Nguyen MD, Julien JP, Rivest J, et al. Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci 2002;3:216-27.
12. Yong VW, Chabot S, Stuve O, et al. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998;51:682-9.
13. Limone P, Ferrero B, Calvelli P, et al. Hypothalamic-pituitary-adrenal axis and cytokine production in MS with or without interferon-beta treatment. Acta Neurol Scand 2002;105:372-7.
14. Liu Z, Pelfrey CM, Cotleur A, et al. Immunomodulatory effects of interferon beta-1b in multiple sclerosis. J Neuroimmunol 2001;112:153-62.
15. Waubant E, Gee L, Miller K, et al. IFN-beta-1a may increase serum levels of TIMP-1 in patients with relapsing-remitting multiple sclerosis. J Interferon Cytokine Res 2001;21:181-5.
16. Trojano M, Avolio C, Liuzzi GM, et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 1999;53:1402-8.
17. Karg E, Klivenyi P, Bencsik K, et al. Alpha-tocopherol and NADPH in the erythrocytes and plasma of multiple sclerosis patients: effect of interferon-beta-1b treatment. Eur Neurol 2003;50:215-9.
18. Floris S, Ruuls SR, Wierinckx A. Interferon-beta directly influences monocyte infiltration into the central nervous system. J Neuroimmunol 2002;127:69-79.
19. Chabot S, Yong VW. Interferon beta-1b increases interleukin-10 in a model of T cell-microglia interaction: relevance to MS. Neurology 2000;55:1497-505.
20. Galboiz Y, Shapiro S, Lahat N, et al. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis. Ann Neurol 2001;50:443-51.
21. Avolio C, Guiliani F, Liuzzi GM, et al. Adhesion molecules and matrix metalloproteinases in multiple sclerosis: effects induced by interferon-beta. Brain Res Bull 2003;61:357-64.
22. Stuve O, Chabot S, Jung SS, et al. Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9. J Neuroimmunol 1997;80:38-46.
23. Corsini E, Gelati M, Dufour A, et al. Effects of beta-IFN-1b treatment in MS patients on adhesion between PBMNCs, HUVECs and MS-HBECs: an in vivo and in vitro study. J Neuroimmunol 1997;79:76-83.
24. Trojano M, Defazio G, Avolio C, et al. Effects of rIFN-beta-1b on serum circulating ICAM-1 in relapsing remitting multiple sclerosis and on membrane bound ICAM-1 expression on brain microvascular endothelial cells. J Neurovirol 2000;6(suppl 2):47-51.
25. Liu H, Xin L, Chan BPL, et al. Interferon-β confers a beneficial outcome in a rabbit model of thromboembolic cerebral ischemia. Neurosci Lett 2002;327:146-8.
26. Veldhuis WB, Derksen JW, Floris S, et al. Interferon-beta blocks infiltration of inflammatory cells and reduces infarct volume after ischemic stroke in the rat. J Cereb Blood Flow Metab 2003;23:1029-39.
27. Veldhuis WB, Floris S, van der Meide PH, et al. Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption. J Cereb Blood Flow Metab 2003;23:1060-9.
28. Allen AR. Surgery of experimental lesion of spinal cord equivalent to crush injury of fracture dislocation of spinal column: a preliminary report. JAMA 1991;57:878-80.
29. Taoka Y, Okajima K, Uchiba M, et al. Role of neutrophils in spinal cord injury in rats. Neuroscience 1997;79:1177-82.
30. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
31. Rivlin AS, Tator CH. Effect of duration of acute spinal cord compression in a new acute cord injury model in the rat. Surg Neurol 1978;10:39-43.
32. Basso DM, Beattie MS, Bresnahan JC. Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection. Exp Neurol 1996;139:244-56.
33. Oliveria IC, Sciavolino PJ, Lee TH, et al. Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc Natl Acad Sci USA 1002;89:9049-53.
34. Yang L, Blumbergs PC, Jones NR, et al. Early expression and cellular localisation of proinflammatory cytokines IL-1β, IL-6 and TNF-in human traumatic cord injury. Spine 2004;29:966-71.
35. Kunnikara T, Sasaki S, Ishikura H, et al. Lazanoid reduces production of IL-8 and IL-1/receptor antagonist in ischemic spinal cord injury. Ann Thorac Surg 2000;69:792-8.
36. Ranhosoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003;3:569-81.
37. Calabresi PA, Prat A, Biernacki K, et al. T lymphocytes conditioned with interferon beta induce membrane and soluble VCAM on human brain endothelial cells. J Neuroimmunol 2001;79:76-83.
38. Lou J, Gashe Y, Zheng L, et al. Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer. Lab Invest 1999;79:1015-25.
39. Xu W, Chi L, Xu R, et al. Increased production of reactive oxygen species contributes to motor neuron death in a compression mouse model of spinal cord injury. Spinal Cord 2005;43:204-13.
40. Fabian RH, Kent TA. Superoxide anion production during reperfusion is reduced by an antineutrophil antibody after prolonged cerebral ischemia. Free Radic Biol Med 1999;26:355-61.
41. Solaroglu I, Kaptanoglu E, Okutan O, et al. Magnesium sulfate treatment decreases caspase-3 activity after experimental spinal cord injury in rats. Surg Neurol 2005;64(suppl 2):17-21.
42. Kaptanoglu E, Tuncel M, Palaoglu S, et al. Comparison effect of melatonin and methylprednisolone in experimental spinal cord injury. J Neurosurg 2000;93:77-84.
43. Kaptanoglu E, Solaroglu I, Okutan O, et al. Erythropoietin exerts neuroprotection after acute spinal cor injury in rats: effects on lipid peroxidation and early ultrastructural findings. Neurosurg Rev 2004;27:113-20.
44. Kaptanoglu E, Caner HH, Surucu SH, et al. Effect of mexiletine on lipid peroxidation and early ultrastructural findings in experimental spinal cord injury. J Neurosurg 1999;91:200-4.
45. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury: results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990;322:1405-11.
46. Rehberg E, Kelder B, Hoal EG, et al. Specific molecular activities of recombinant and hybrid leukocyte interferons. J Biol Chem 1982;257:1497-502.
47. Wintergerst U, Belohradsky BH. Acyclovir monotherapy versus acyclovir plus beta-interferon in focal viral encephalitis in children. Infection 1992;20:207-12.
48. Wintergerst U, Kugler K, Harms F, et al. Therapy of focal viral encephalitis in children with acyclovir and recombinant beta-interferon: results of a placebo-controlled multicenter study. Eur J Med Res 2005;10:527-31.